All In Biotech

Drug Trial Radar · NCT01000025

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease

Last checked: Nov 20, 2026Latest source record: Aug 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 720 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

720

Actual

Start

Dec 23, 2009

Primary completion

Jan 15, 2014

Study completion Nov 27, 2015

Sponsor

Lead sponsor
NCIC Clinical Trials GroupResearch network
Sponsor type
Research network
Collaborators
Pfizer
First posted
Oct 22, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: PF-00299804 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether PF-00299804 is more effective than a placebo in treating patients with advanced non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying PF-00299804 to see how well it works compared with a placebo in treating patients with stage IIIB or stage IV non-small cell lung cancer that has not responded to standard therapy for advanced or metastatic cancer.

Conditions

  • Lung Cancer

Interventions

  • PF-00299804Drug

    PF-804 45 mg PO, daily

  • PlaceboDrug

    Placebo 45 mg PO, daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: 42 Months

Locations

89 sites in 12 countries. Site status is shown where the registry gives one.

  • Shapiro, Stafford and Yee

    Arcadia, California

  • Clintell, Inc.

    Skokie, Illinois

  • Damic-Fundacion Rusculleda

    Córdoba, Argentina

  • Centro Medico San Roque

    San Miguel de Tucumán, Argentina

  • CER - Instituto Medico

    Buenos Aires, B1878dvb Bs. As., Argentina

  • COIBA Centro de Oncologia e Investigacion

    Berazategui, Buenos Aires, Argentina

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia

  • St. George Hospital, Cancer Care Centre

    Kogarah, New South Wales, Australia

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • Calvary Mater Newcastle Hospital

    Waratah, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • The Prince Charles Hospital

    Chermside, Queensland, Australia

  • Nambour General Hospital

    Nambour, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Western Hospital

    Footscray, Victoria, Australia

  • Frankston Hospital - Peninsula Oncology Centre

    Frankston, Victoria, Australia

  • Geelong Hospital

    Geelong, Victoria, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • Sir Charles Gairdner Hospital

    Perth, Western Australia, Australia

  • Oxion Hospital Dia Oncologia LTDA - Oxion

    Belo Horizonte, Brazil

  • Site not named

    Centro, Brazil

  • Nucleo de Oncologia da Bahia

    Salvador, Brazil

  • GRAM - Grupo de Assistencia Medica

    São Paulo, Brazil

  • Centro de Oncologia e Radioterapia (COR) Mae de Deus

    Porto Alegre, Rio Grande do Sul, Brazil

  • Fundacao Pio XII - Hospital de Cancer de Barretos

    Barretos, São Paulo, Brazil

  • ESHO - Empresa de Servicos Hospitalares Ltda.

    Brasilia, São Paulo, Brazil

  • Centro de Pesquisa Clinica do Hospital

    Porto Alegre, São Paulo, Brazil

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • BCCA - Abbotsford Centre

    Abbotsford British Columbia, British Columbia, Canada

  • BCCA - Fraser Valley Cancer Centre

    Surrey, British Columbia, Canada

  • BCCA - Vancouver Cancer Centre

    Vancouver, British Columbia, Canada

  • Atlantic Health Sciences Corporation

    Saint John, New Brunswick, Canada

  • Dr. H. Bliss Murphy Cancer Centre

    St. John's, Newfoundland and Labrador, Canada

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • Health Sciences North

    Greater Sudbury, Ontario, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • Cancer Centre of Southeastern Ontario at Kingston

    Kingston, Ontario, Canada

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.